Kamada (NASDAQ:KMDA) Coverage Initiated at Stifel Nicolaus

Equities research analysts at Stifel Nicolaus started coverage on shares of Kamada (NASDAQ:KMDA) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $18.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 249.51% from the company’s current price.

Other analysts have also recently issued research reports about the stock. StockNews.com began coverage on shares of Kamada in a report on Thursday, June 27th. They issued a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, May 9th.

Kamada Stock Up 3.0 %

NASDAQ KMDA opened at $5.15 on Wednesday. The stock’s 50-day simple moving average is $5.26 and its two-hundred day simple moving average is $5.61. Kamada has a twelve month low of $4.08 and a twelve month high of $6.53. The company has a market capitalization of $296.02 million, a price-to-earnings ratio of 22.39 and a beta of 1.06.

Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). Kamada had a return on equity of 5.50% and a net margin of 8.33%. The business had revenue of $37.74 million during the quarter, compared to analysts’ expectations of $38.01 million. On average, equities analysts expect that Kamada will post 0.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kamada

Several hedge funds and other institutional investors have recently modified their holdings of the stock. EWA LLC purchased a new position in Kamada in the 4th quarter worth approximately $68,000. Y.D. More Investments Ltd grew its stake in Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 15,000 shares in the last quarter. Calton & Associates Inc. bought a new position in shares of Kamada during the 4th quarter worth $111,000. Aristides Capital LLC lifted its position in shares of Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares in the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.